Relationship between Anaplastic Lymphoma Kinase Inhibitors and Seizure Disorders: A Post-Marketing Surveillance Study

This pharmacovigilance study analyzed FDA adverse event reports to investigate whether ALK inhibitors (crizotinib, ceritinib, alectinib, brigatinib, lorlatinib) are associated with seizures using Bayesian statistical methods. Results showed varying signal detection scores across different ALK inhibitors, with ceritinib, brigatinib, alectinib, and lorlatinib demonstrating stronger associations with seizure disorders compared to crizotinib.